We examined the durability of the virological response after discontinuing lamivudine ( LVD ) in chronic hepatitis B ( CHB ) patients with LVD-resistant hepatitis B virus ( HBV ) , who responded to LVD plus adefovir ( ADV ) combination therapy , and the outcome of switching to ADV monotherapy compared to maintaining combination therapy .